avac. used to be the aids vaccine advocacy coalition. we're now avav i'm on the board. we have a big conflict of interest. mitchell talks about the where the research is from a leading advocacy organization focused on hiv prevention. a margie mcglynn is here that runs the international aids vaccine initiative. iavi. runs one of the partnerships bringing together a multiple set of actors to accelerate the development of an hiv vaccine to hear from here where iavi is and where her partners and prospective from leading pdp in this area. format we'll have 30 minutes for dr. fauci to give us sort after presentation, plenary talk and we'll move to mitchell warren of avac of eight other ten minutes of comments. margie mcglynn as well eight or ten minutes of comments. then we'll open up the pan fell for you to give questions and i will moderate that. a good chance for to you engage with them on discussions where we are with hiv vaccine research and where it is coming. so, dr. faw economy, over -- fauci, over to you, and thank you for coming. [applause] >> so i can advance my ow

i am on the board of avac, so a big conflict of interest there. margie mcglynn is here with us. she runs the international aids vaccine initiative. it is one of the product development partnerships that is focused on bringing together multiple sets of actors to accelerate the development of an hiv vaccine. it will be a great opportunity to hear from her and what she sees in her perspective. we will have about 30 minutes for dr. fauci to give us a presentation, plenary talk, and move to mitchell for about 10 minutes, and then margie mcglynn for about 10 minutes as well. and then we'll open it up to the panel for you to engage them in questions and answers. i will moderate that. it is a good chance for you to engage with them on discussions around where we are with hiv research and how it fits in. dr. fauci, over to you. thank you again for coming. [applause] >> so i can advance my own slides? there you go. thank you. thank you very much, todd. it's a real pleasure to be here with you today. i will talk about the issue of the role of an hiv vaccine. i want to start off by putting

mitchell warren runs avac. one of their job system to bring the community into these discussions, he needs to translate some of the b-cell, envelopes, into languages people like me understand. we asked mitchell to do, to how do you generate the advocates to make sure they have adequate -- former secretary of health, and a former president gave us ten years, we keep running on. one of the thing that is mitchell has to do is to get people excited to keep the money flowing and so they don't get ahead of progress. >> mitchell. >> the magic is being introduced by a board member, the hard part is following mr. translating complex science to a range of people, and issues back, someone working in the field, we often see people compart mentalized. i am i think dr. fauchi is a translator as much as as of us, when when they come together, it is try for hip, and i was thinking bl what to say after dr. voucher, i went back seven years ago, we did a bit of a sound track. three different. my favorite is that is "we are on a r

we have joining us, mitchell warren, who runs a vac, now, avac, i am on the board. a big conflict of interest there. mitchell will talk about some of the perspectives where the research is from the organization, focused on hiv prevention. and margie runs the hiv initiative. product development partnerships, focused on bringing together a multiple sets of actors to it will be a great opportunity to hear from her, where the partners are, and the leading pdp in this area. for format, about 30 minutes for dr. fauchi, to give a presentation, and then, we move to mitchell warren, eight or ten minutes of comments, margie mcglenn, and then, open it up for the panel for you to engage them in questions and answers, i will moderate that. that is a good chance for you to see where we are with hiv research, dr. fauchi, over to you. thank you for coming. it is a pleasure to be here with you today. i am going to talk a bit about the issue of the role of an hiv vaccine. i want to start off by putting into perspective the concept of why we really do need an hiv hax vine, despite the

[laughter] avac and onen runs theheir jobs is to bring audience induces discussion -- into the discussion. one of the things we asked mitchell to do was to talk a little bit about how you generate the kind of advocates you need so that dr. fauci and his team have adequate resources, but not getting too far ahead? we keep running on. one of the things mitchell has to do is to figure out how to get people excited enough that they keep the money flowing, but not so excited that they get ahead of our progress. [applause] >> we will see if it's magic. by magic is being introduced a board member. the harder thing is following dr. fauci. we talk about being a translation organization, scienceing very complex and competent issues into the science. field, we often see people become carp -- compartmentalized. here asrrassed to be up the advocate for the translator, when i think dr. fauci is an advocate and a translator as much as any of us. we often forget that. if we learn anything in the 30 plus years of this epidemic, is that when these constituencies come together it is true for hiv and it is c

avac. used to be the aids vaccine advocacy coalition. we're now avav i'm on the board. we have a big conflict of interest. mitchell talks about the where the research is from a leading advocacy organization focused on hiv prevention. a margie mcglynn is here that runs the international aids vaccine initiative. iavi. runs one of the partnerships bringing together a multiple set of actors to accelerate the development of an